Loading...
•
Jun 30, 2020
ALX Oncology Q2 2020 Earnings Report
Reported financial results for the second quarter ended June 30, 2020, and provided operational and clinical development highlights.
Key Takeaways
ALX Oncology reported second quarter financial results, highlighting the completion of their initial public offering in July 2020, which raised gross proceeds of $185.7 million. The company's lead development candidate, ALX148, is advancing in multiple clinical trials, and the company believes its cash balance is sufficient to fund planned operations through 2023.
Completed initial public offering of common stock on July 21, 2020, raising gross proceeds of $185.7 million.
Strengthened leadership team and expanded board of directors to support growth.
IND open for ALX148 in combination with azacitidine for first-line treatment of patients with higher risk myelodysplastic syndromes (MDS).
ALX148 displayed a favorable tolerability profile with no exposure-dependent cytopenia observed across the dose range evaluated.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...